Quote this publication Share Print

DEFITELIO

-
Opinions on drugs - Posted on Oct 13 2014

Reason for request

Inclusion

-


Actual benefit

Modéré

the actual benefit of DEFITELIO is moderate in the Marketing Authorisation indication.


Improvement in actual benefit

IV (mineur)

In light of the available data which have a low level of evidence even though there are study designs only requiring a few patients, and due to the severity of the disease and the absence of an alternative, the Committee considers that DEFITELIO provides a minor improvement in actual benefit (IAB IV) in the therapeutic strategy for treatment of severe hepatic VOD post-HCST.


Ce produit fait l'objet d'un avis d'efficience rendu par la Commission évaluation économique et santé publique le 18 février 2014

See also